<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 15 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><title>ANNOUNCING Active Surveillance/Low Risk Prostate Cancer Webinar Series 2020</title><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Cambria;
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:"Helvetica Neue";}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
span.EmailStyle43
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:58987939;
mso-list-template-ids:-1603096056;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:72.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:108.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:144.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:180.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:216.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:252.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:288.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:324.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:915211773;
mso-list-template-ids:-1267451348;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:72.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:108.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:144.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:180.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:216.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:252.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:288.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:324.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2
{mso-list-id:1466699352;
mso-list-template-ids:-742626448;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:72.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:108.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:144.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:180.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:216.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:252.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:288.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:324.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3
{mso-list-id:1546521027;
mso-list-template-ids:1566069906;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:72.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:108.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:144.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:180.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:216.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:252.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:288.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:324.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4
{mso-list-id:1606763056;
mso-list-template-ids:-667619724;}
@list l4:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:72.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l4:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:108.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:144.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:180.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:216.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:252.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:288.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:324.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5
{mso-list-id:2009208466;
mso-list-template-ids:100164488;}
@list l5:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:72.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l5:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:108.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:144.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:180.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:216.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:252.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:288.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:324.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0cm;}
ul
{margin-bottom:0cm;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body bgcolor="#FAFAFA" lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'>See below for a note from Phil Segal, the past Chair of PCCN T.O., wrt a series of on-line seminars being put on by US-Too.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'>US-Too is the foremost PCa support organization.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'>Take care & stay well.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #E1E1E1 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:11.0pt;font-family:"Calibri",sans-serif'>From:</span></b><span lang=EN-US style='font-size:11.0pt;font-family:"Calibri",sans-serif'> Philip Segal <br><b>Sent:</b> July 10, 2020 4:02 PM<br><b>To:</b> Philip Segal <segalfamily@sympatico.ca><br><b>Subject:</b> FW: ANNOUNCING Active Surveillance/Low Risk Prostate Cancer Webinar Series 2020<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;color:#1F497D'>Good Afternoon<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;color:#1F497D'>I just wanted to let you know about a great set of on-line seminars over the next 6 months being put on by Us-Too in the States<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;color:#1F497D'>These deal with various aspects of Active Surveillance and the presenters are really top- notch<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;color:#1F497D'>I’d like to support the people behind this project so I’m forwarding this notice to you in the hope that you’ll forward it on through your mailing lists so they can really get the seminars well attended<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;color:#1F497D'>Thanks for your consideration<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;color:#1F497D'>Regards<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;color:#1F497D'>Phil Segal<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;color:#1F497D'>PCCN-Toronto<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma",sans-serif'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma",sans-serif'> AnCan Webinars [<a href="mailto:webinar@ancan.org">mailto:webinar@ancan.org</a>] <br><b>Sent:</b> July 10, 2020 12:26 PM<br><b>To:</b> Philip<br><b>Subject:</b> ANNOUNCING Active Surveillance/Low Risk Prostate Cancer Webinar Series 2020<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:#FAFAFA;border-collapse:collapse'><tr><td width="100%" valign=top style='width:100.0%;padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td valign=top style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:#26ABE2;border-collapse:collapse'><tr><td valign=top style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=640 style='width:480.0pt;border-collapse:collapse'><tr><td valign=top style='padding:6.75pt 0cm 6.75pt 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td valign=top style='padding:6.75pt 0cm 0cm 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;margin-left:-2.25pt;margin-right:-2.25pt'><tr><td width=320 valign=top style='width:240.0pt;padding:0cm 0cm 0cm 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse'><tr><td valign=top style='padding:0cm 13.5pt 6.75pt 13.5pt'><p class=MsoNormal align=center style='text-align:center;line-height:125%'><span style='font-size:10.5pt;line-height:125%;font-family:"Helvetica Neue";color:#FAFAFA'>A Message from the AnCan Virtual Support Groups</span><span style='font-size:7.5pt;line-height:125%;font-family:"Helvetica",sans-serif;color:#FAFAFA'><o:p></o:p></span></p></td></tr></table></td><td width=320 valign=top style='width:240.0pt;padding:0cm 0cm 0cm 0cm;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;word-break:break-word'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left style='max-width:240.0pt;border-collapse:collapse;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><tr><td valign=top style='padding:0cm 13.5pt 6.75pt 13.5pt;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><p class=MsoNormal align=center style='text-align:center;line-height:125%'><span style='font-size:10.5pt;line-height:125%;font-family:"Helvetica Neue";color:#FAFAFA'><a href="https://mailchi.mp/609972b075f3/announcing-active-surveillancelow-risk-prostate-cancer-webinar-series-2020?e=04070b1cfb" target="_blank"><span style='color:#FAFAFA'>View this email in your browser</span></a></span><span style='font-size:7.5pt;line-height:125%;font-family:"Helvetica",sans-serif;color:#FAFAFA'><o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table></td></tr></table></div></td></tr></table></div></td></tr><tr><td valign=top style='padding:0cm 0cm 0cm 0cm;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:#FAFAFA;border-collapse:collapse;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%' id=templateHeader><tr><td valign=top style='padding:0cm 0cm 0cm 0cm;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=640 style='width:480.0pt;border-collapse:collapse;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><tr><td valign=top style='padding:6.75pt 0cm 6.75pt 0cm;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><tr><td valign=top style='padding:6.75pt 6.75pt 6.75pt 6.75pt;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=293 style='width:219.75pt;border-collapse:collapse;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><tr><td valign=top style='padding:0cm 0cm 0cm 6.75pt;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><p class=MsoNormal><img border=0 width=187 height=90 style='width:1.9479in;height:.9375in' id="_x0000_i1029" src="https://mcusercontent.com/ece3f3da90f82cb974b407396/images/918e7663-5380-4401-8b1d-8f743fa34e02.jpg"><o:p></o:p></p></td></tr></table><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=right width=293 style='width:219.75pt;border-collapse:collapse'><tr><td valign=top style='padding:0cm 6.75pt 0cm 0cm'><p class=MsoNormal><img border=0 width=284 height=84 style='width:2.9583in;height:.875in' id="_x0000_i1028" src="https://mcusercontent.com/ece3f3da90f82cb974b407396/images/d7e3313f-3b09-4e9e-b691-0e6bdfb43e59.jpg"><o:p></o:p></p></td></tr></table></td></tr></table><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width: 100%;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><tr><td valign=top style='padding:6.75pt 6.75pt 6.75pt 6.75pt;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><tr><td valign=top style='padding:0cm 6.75pt 0cm 6.75pt;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><p class=MsoNormal align=center style='text-align:center'><img border=0 width=604 height=781 style='width:6.2916in;height:8.1354in' id="_x0000_i1027" src="https://mcusercontent.com/ece3f3da90f82cb974b407396/images/679bfe02-d17b-4ff5-a995-221a0a6e8f13.png"><o:p></o:p></p></td></tr></table></td></tr></table><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif'><o:p></o:p></span></p></td></tr></table></div></td></tr></table></div></td></tr><tr><td valign=top style='padding:0cm 0cm 0cm 0cm;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:#FAFAFA;border-collapse:collapse;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%' id=templateBody><tr><td valign=top style='padding:0cm 0cm 0cm 0cm;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=640 style='width:480.0pt;border-collapse:collapse;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><tr><td valign=top style='padding:6.75pt 0cm 6.75pt 0cm;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'></td></tr></table></div></td></tr></table></div></td></tr><tr><td valign=top style='padding:0cm 0cm 0cm 0cm;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:#FAFAFA;border-collapse:collapse;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%' id=templateFooter><tr><td valign=top style='padding:0cm 0cm 0cm 0cm;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=640 style='width:480.0pt;border-collapse:collapse;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><tr><td valign=top style='padding:6.75pt 0cm 6.75pt 0cm;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><tr><td style='padding:13.5pt 13.5pt 27.0pt 13.5pt;min-width: 100%;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width: 100%;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><tr><td style='border:none;border-top:solid #DDDDDD 1.0pt;padding:0cm 0cm 0cm 0cm;min-width: 100%;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'></td></tr></table></td></tr></table><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width: 100%;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><tr><td valign=top style='padding:6.75pt 0cm 0cm 0cm;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;margin-left:-2.25pt;margin-right:-2.25pt;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><tr><td width=640 valign=top style='width:480.0pt;padding:0cm 0cm 0cm 0cm;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;max-width:100%;min-width: 100%;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><tr><td valign=top style='padding:0cm 13.5pt 6.75pt 13.5pt;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;word-break:break-word'><p class=MsoNormal align=center style='text-align:center;line-height:150%'><strong><i><span style='font-size:13.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#222222'>Pioneer Speaks About Active Surveillance for Prostate Cancer</span></i></strong><b><i><span style='font-size:13.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#222222'><br><strong><span style='font-family:"Helvetica",sans-serif'>Dr. Peter Carroll launches webinar series July 30</span></strong></span></i></b><span style='font-size:7.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#222222'><br> <o:p></o:p></span></p><p class=MsoNormal style='line-height:150%'><span style='font-size:7.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#222222'><br><a href="https://ancan.us14.list-manage.com/track/click?u=ece3f3da90f82cb974b407396&id=1fbf6e2c71&e=04070b1cfb" target="_blank"><strong><i><span style='font-size:13.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'>AnCan</span></i></strong></a></span><span style='font-family:"Helvetica",sans-serif;color:#222222'><a href="https://ancan.us14.list-manage.com/track/click?u=ece3f3da90f82cb974b407396&id=968a351fb5&e=04070b1cfb"><span style='color:#202020'> </span></a>and <a href="https://ancan.us14.list-manage.com/track/click?u=ece3f3da90f82cb974b407396&id=0e066f125a&e=04070b1cfb" target="_blank"><strong><i><span style='font-family:"Helvetica",sans-serif;color:#202020'>Us Too International</span></i></strong><em><span style='font-family:"Helvetica",sans-serif;color:#202020'>,</span></em></a> sponsors of support groups for men with prostate cancer, today announced a series of four webinars, </span><em><b><span style='font-size:13.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#222222'>Active Surveillance & Beyond,</span></b></em><span style='font-family:"Helvetica",sans-serif;color:#222222'> aimed at men on or considering active surveillance (AS) for low- and intermediate-risk prostate cancer in place of aggressive therapy.<br><br>Dr. Peter Carroll, one of the pioneers of the AS approach of monitoring these cancers, will kick off the series on July 30 at 8 p.m. Eastern. His topic is<strong><i><span style='font-family:"Helvetica",sans-serif'> “The Past, Present, and Future of Active Surveillance.”</span></i></strong> Dr. Carroll stepped down earlier this year as Chair of Urology at the University of California, San Francisco, but remains an active researcher.<br><br><strong><span style='font-family:"Helvetica",sans-serif'>ASPI (Active Surveillance Patients Internationa), PCRI (Prostate Cancer Research Institute), and ZERO - The End of Prostate Cancer co-sponsor the webinars.</span></strong></span><span style='font-size:7.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#222222'><br><br></span><strong><i><span style='font-size:13.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#222222'>To register </span></i></strong><span style='font-family:"Helvetica",sans-serif;color:#222222'>for the July 30 webinar with Dr. Carroll, go to<br><a href="https://ancan.us14.list-manage.com/track/click?u=ece3f3da90f82cb974b407396&id=f02c6e325f&e=04070b1cfb" target="_blank"><span style='color:#202020'>https://attendee.gotowebinar.com/register/8711469517744476428</span></a><br><br>To submit questions ahead of the July 30 session or for information, write to <a href="mailto:joeg@ancan.org?subject=AS%20Webinars%20-%20Question" target="_blank"><span style='color:#202020'>joeg@ancan.org</span></a><br><br><br><br><u>Other webinars in the AS & Beyond series are </u>:</span><span style='font-size:7.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#222222'><br> <o:p></o:p></span></p><ul type=disc><li class=MsoNormal style='color:#222222;mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:150%;mso-list:l5 level1 lfo3;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><strong><i><span style='font-family:"Helvetica",sans-serif'>September 29. Dr. Brian Helfand</span></i></strong><span style='font-family:"Helvetica",sans-serif'>, Division Chief of Urology, NorthShore University <br>HealthSystem, Glenview, Illinois, will discuss where things stand and where they are <br>heading with genomic testing in decision-making for AS.</span><span style='font-size:7.5pt;line-height:150%;font-family:"Helvetica",sans-serif'><o:p></o:p></span></li></ul><p class=MsoNormal style='line-height:150%'><span style='font-size:7.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#222222'> <o:p></o:p></span></p><ul type=disc><li class=MsoNormal style='color:#222222;mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:150%;mso-list:l4 level1 lfo6;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><strong><i><span style='font-family:"Helvetica",sans-serif'>November 30. Dr. Antonio Westphalen</span></i></strong><span style='font-family:"Helvetica",sans-serif'>, Chief of Abdominal Imaging, University of Washington at Seattle, will discuss his research on the value of monitoring men on AS with multiparametric MRIs and how to find the best radiologist to read your MRI.</span><span style='font-size:7.5pt;line-height:150%;font-family:"Helvetica",sans-serif'><o:p></o:p></span></li></ul><p class=MsoNormal style='line-height:150%'><span style='font-size:7.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#222222'> <o:p></o:p></span></p><ul type=disc><li class=MsoNormal style='color:#222222;mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;line-height:150%;mso-list:l1 level1 lfo9;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%'><strong><i><span style='font-family:"Helvetica",sans-serif'>December 30. Dr. Jonathan Epstein</span></i></strong><span style='font-family:"Helvetica",sans-serif'>, Chair of Urological Pathology, The JohnsHopkins Medical Institutions in Baltimore, will speak about critical issues of grading prostate cancer for patients considering AS.</span><span style='font-size:7.5pt;line-height:150%;font-family:"Helvetica",sans-serif'><o:p></o:p></span></li></ul><p class=MsoNormal style='line-height:150%'><span style='font-size:7.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#222222'><br></span><span style='font-family:"Helvetica",sans-serif;color:#222222'>#AS&Beyond #activesurveillance #Gleason6 #ProstateCancer</span><span style='font-size:7.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#222222'><o:p></o:p></span></p><p class=MsoNormal style='line-height:150%'><span style='font-size:7.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#222222'> <o:p></o:p></span></p><p class=MsoNormal style='line-height:150%'><span style='font-size:7.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#222222'> <o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif'><o:p></o:p></span></p></td></tr></table></div></td></tr></table></div></td></tr></table></div></td></tr></table></div><p class=MsoNormal align=center style='margin-bottom:12.0pt;text-align:center'><br><br><br><br><o:p></o:p></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:white;border-collapse:collapse' id=canspamBarWrapper><tr><td valign=top style='border:none;border-top:solid #E5E5E5 1.0pt;padding:15.0pt 0cm 15.0pt 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse' id=canspamBar><tr><td valign=top style='padding:0cm 15.0pt 3.75pt 15.0pt'><p class=MsoNormal align=center style='text-align:center;line-height:150%'><span style='font-size:8.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#606060'><br>AnCan Foundation · 1104 Hawthorne Circle · Shakopee, MN 55379 · USA <br><br></span><a href="http://www.mailchimp.com/email-referral/?utm_source=freemium_newsletter&utm_medium=email&utm_campaign=referral_marketing&aid=ece3f3da90f82cb974b407396&afl=1"><span style='font-size:8.5pt;line-height:150%;font-family:"Helvetica",sans-serif;text-decoration:none'><img border=0 width=139 height=54 style='width:1.4479in;height:.5625in' id="_x0000_i1026" src="https://cdn-images.mailchimp.com/monkey_rewards/MC_MonkeyReward_15.png" alt="Email Marketing Powered by Mailchimp"></span></a><span style='font-size:8.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#606060'><o:p></o:p></span></p></td></tr></table></div></td></tr></table></div><p class=MsoNormal><img border=0 width=1 height=1 style='width:.0104in;height:.0104in' id="_x0000_i1025" src="https://ancan.us14.list-manage.com/track/open.php?u=ece3f3da90f82cb974b407396&id=ec99facb7d&e=04070b1cfb"><o:p></o:p></p></div></body></html>